The “Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030
Key Inclusions
§ A detailed assessment of theoverall landscape of companies with capabilities for continuous manufacturing,along with information on a number of relevant parameters, such as year ofestablishment, company size, purpose of manufacturing (in-house and contractservices), scale of operation (preclinical, clinical and commercial), locationof headquarters, location of manufacturing facilities, type of drug molecule(biologic and small molecule), type of continuous manufacturing relatedservice(s) offered (process development, API manufacturing, intermediatemanufacturing, drug product manufacturing, and packaging and fill /finish), type of dosage form (solid andliquid), and installed capacity and batch size (if available).
§ Elaborate profiles ofsome of the key contract manufacturers active in the pharmaceutical andbiopharmaceutical continuous manufacturing market in North America, Europe andAsia-Pacific. Each profile features an overview of the company, along withinformation related to its service portfolio, continuous manufacturingcapabilities and facilities, recent developments and an informed futureoutlook.
§ An analysis of thevarious partnerships related to continuous manufacturing, which have beenestablished since 2013, based on several parameters, such as year of anagreement, the type of partnership (research agreements, facility development /establishment agreements, technology enhancement agreements, service alliances,process development agreements, manufacturing agreements and other relevant agreements),scale of operation (preclinical, clinical and commercial), type of drugmolecule (biologic and small molecule), type of continuous manufacturingrelated service (API manufacturing, intermediate manufacturing and end productmanufacturing) and type of dosage form (solid and liquid). It also provides theregional distribution of the collaborations.
§ An analysis of theexpansions related to continuous manufacturing, which have been establishedsince 2013, based on several parameters, such as year of an expansion and thetype of expansion (facility / plant expansion, technology installation,technology enhancement and service expansion), geographical location of thefacility, scale of operation (preclinical, clinical and commercial), type ofdrug molecule (biologic and small molecule), type of continuous manufacturingrelated service (API manufacturing, intermediate manufacturing and end productmanufacturing) and type of dosage form (solid and liquid).
§ An estimate of theglobal, continuous manufacturing capacity, based on the capacities of variousindustry stakeholders (as available on their respective company websites). Thestudy examines the distribution of capacity, based on the type of drug molecule(biologic and small molecule), company size (small-sized, mid-sized and large),scale of operation (preclinical, clinical and commercial), location ofheadquarters (North America, Europe and Asia-Pacific) and location of manufacturing facilities (North America,Europe and Asia-Pacific).
§ A study of thevarious grants that have been awarded to research institutes engaged inprojects related to continuous manufacturing, between 2014 and 2019,highlighting multiple parameters, such as year of award, type of grant, grantamount, focus area, support period, popular recipient organizations, type ofrecipient organization, funding institute center, funding mechanism andprominent program officers.
§ An in-depth analysisof the various patents that have been filed / granted related to continuous manufacturingtill 2019. It includes information on key parameters, such as patent type,publication year, geographical location, CPC symbol, emerging focus areas, typeof applicant and leading industry / non-industry players (in terms of the sizeof intellectual property portfolio). It also features a three-dimensionalbubble analysis (based on patent citation count, publication year, extendedgeographical reach), as well as a patent benchmarking and a detailed valuationanalysis.
§ Initiatives taken bythe leading pharmaceutical companies (in terms of revenues), covering bothpartnered as well as in-house projects.
§ A review of thecompanies offering modular facilities / modular cleanrooms, with information ontheir geographical location (North America, Europe, Asia-Pacific and rest ofthe world), year of establishment, company size (small-sized, mid-sized orlarge) and type of industries served (pharmaceutical, biotechnology or others).It also includes information on the recent projects undertaken / executed bythe companies providing modular facilities.
§ A case study of thecompanies offering technologies / equipment (continuous blenders and mixers,continuous granulators, continuous dryers, continuous compressors, continuouscoaters, flow reactors, continuous filtration, distillation and centrifugationequipment, continuous chromatography, PAT technology and other technologies)that can potentially be used in a continuous manufacturing process, providinginformation on the geographical location of potential stakeholders and the typeof technology / equipment provided.
§ A case study on theroadmap for the adoption of continuous manufacturing technique, discussingdifferent strategies that can be followed by the company in order to adopt thistechnology or transition from batch manufacturing to continuous manufacturing.
The report also features the likelydistribution of the current and forecasted opportunity across important marketsegments, mentioned below:
§ Purposeof Manufacturing
§ In-House
§ Contract service
§ Scaleof Operation
§ Commercial
§ Preclinical /Clinical
§ Typeof Continuous Manufacturing related Service
§ APIManufacturing
§ EndProduct manufacturing
§ Typeof Drug Molecule
§ Biologic
§ Small Molecule
§ Typeof dosage form
§ Solid
§ Liquid
§ KeyGeographical Regions
§ North America
§ Europe
§ Asia Pacific
§ Transcripts of interviews held with the following seniorlevel representatives of stakeholder companies
§ Andrea Adamo, Founderand Chief Executive Officer, Zaiput Flow technologies
§ Bayan Takizawa, Co-Founderand Chief Business Officer, CONTINUUS Pharmaceuticals
§ Nick Thomson, SeniorDirector Chemical Research and Development, Pfizer
§ Himanshu Gadgil, Directorand Chief Scientific Officer, Enzene Biosciences
§ Eric Fang, ChiefScientific Officer, Snapdragon Chemistry)
§ Ian Houson, TechnicalProject Manager, Continuous Manufacturing and Crystallization, University ofStrathclyde
To request sample pages, please visit this - https://www.rootsanalysis.com/reports/308/request-sample.html
Key Questions Answered
§ Who are the keyplayers engaged in continuous manufacturing of small molecules and biologics?
§ Whatis the installed, global capacity for continuous manufacturing?
§ Whatare the key growth drivers within this domain?
§ Whatare the various paths to evolution within this industry?
§ Whoare the other key stakeholders (modular facility providers and technology /equipment developers) in this domain?
§ How is the currentand future market opportunity likely to be distributed across key marketsegments?
You may also be interested in the following titles:
1. Pharmaceutical Contract ManufacturingMarket (2nd Edition), 2018-2028
2. Biopharma Contract Manufacturing Market (3rd Edition), 2019 - 2030
3. China Pharmaceutical Contract Manufacturing Services Market, 2020-2030
4. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
